United Therapeutics (UTHR) Misses Q2 EPS, Revenues Beat
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
Revenue Growth %: -1.2%
Financial Fact:
Total other (expense) income, net: 500K
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: -1.2%
Financial Fact:
Total other (expense) income, net: 500K
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.41, $1.97 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $466.9 million versus the consensus estimate of $460.67 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- StoneX Reiterates Hold Rating on Old Dominion Freight Line (ODFL) on QTD Operating Metrics
- RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
